Peptide Dimer Synthesis for Selective Alpha4beta7 Integrin Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for integrin antagonist molecules with high affinity for the α4β7 integrin and high selectivity against the α4β1 integrin as a therapy for gastrointestinal autoimmune diseases, as existing therapies often result in dangerous side effects due to interference with α4β1 integrin-ligand interactions.
Innovation Solution
The development of peptide dimer compounds synthesized using solid phase and solution phase peptide synthesis methods, incorporating intramolecular disulfide bonds and linkers, to create high-purity peptide dimers with specific sequences that target α4β7 integrin while minimizing interaction with α4β1 integrin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing integrin antagonist therapies are used to treat gastrointestinal autoimmune diseases, then anti-inflammatory effects are achieved, but dangerous side effects occur due to interference with α4β1 integrin-ligand interactions
Solution Approach 1:
The peptide dimer is designed with specific local structural features including intramolecular disulfide bonds and specific amino acid sequences that enable selective binding to α4β7 integrin. The disulfide bonds create a constrained three-dimensional structure that recognizes α4β7-specific epitopes while avoiding α4β1 binding sites, achieving local structural optimization for selective antagonism.
Solution Approach 2:
The peptide dimer employs asymmetric structural design where two different peptide monomers are linked together. Each monomer contains specific asymmetric amino acid sequences and disulfide bond configurations that create a non-symmetric overall structure, enabling differential recognition of α4β7 versus α4β1 integrins and achieving selective binding through structural asymmetry.
2Reliability
If high affinity binding to α4β7 integrin is achieved, then therapeutic effectiveness is improved, but selectivity against α4β1 integrin must be maintained to avoid side effects
Solution Approach 1:
The antagonist is segmented into two separate peptide monomers that are linked to form a dimer. Each monomer contains specific amino acid sequences and disulfide bonds that contribute to overall binding affinity. This segmentation allows independent optimization of each monomer's structure to enhance α4β7 binding while maintaining selectivity, as the combined dimer structure achieves high affinity without cross-reactivity with α4β1.
Solution Approach 2:
The peptide dimer utilizes specific parameter optimizations including disulfide bond placement, amino acid sequence composition, and molecular weight characteristics to achieve high affinity for α4β7 integrin. By carefully controlling these parameters during synthesis and structural design, the molecule achieves nanomolar-range binding affinity for α4β7 while maintaining selectivity against α4β1 through precise structural parameter optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized peptide dimers effectively target α4β7 integrin with high specificity, potentially reducing side effects associated with α4β1 integrin interference, offering a more effective treatment for gastrointestinal autoimmune diseases.
Implementation Method 1
introducing an intramolecular disulfide bond between two residues of the peptide (or allowing the intramolecular bond to form)
Data Source
AI summary
The present invention provides methods of making α4β7 peptide monomer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.